Free Trial

PTC Therapeutics (PTCT) Insider Trading & Ownership

PTC Therapeutics logo
$41.96 +2.60 (+6.61%)
(As of 11/20/2024 ET)

PTC Therapeutics (NASDAQ:PTCT) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
5.50%
Number Of
Insiders Buying
(Last 12 Months)
1
Amount Of
Insider Buying
(Last 12 Months)
$198,737.00
Number Of
Insiders Selling
(Last 12 Months)
10
Amount Of
Insider Selling
(Last 12 Months)
$1.79 M
Get PTCT Insider Trade Alerts

Want to know when executives and insiders are buying or selling PTC Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

PTCT Insider Buying and Selling by Quarter

PTC Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/16/2024Pierre GravierCFOSell2,269$34.02$77,191.38  
5/22/2024Jerome B ZeldisDirectorSell20,000$38.24$764,800.00  
5/7/2024Lee Scott GoldenEVPSell175$32.82$5,743.50  
4/19/2024Matthew B KleinCEOSell3,361$24.89$83,655.29  
4/17/2024Eric PauwelsCEOSell787$25.14$19,785.18  
4/2/2024Lee Scott GoldenEVPSell526$28.37$14,922.62  
1/30/2024Christine Marie UtterCAOSell318$27.25$8,665.50  
1/30/2024Mark Elliott BouldingVPSell794$27.25$21,636.50  
1/30/2024Neil Gregory AlmsteadInsiderSell618$27.25$16,840.50  
1/22/2024Allan Steven JacobsonDirectorSell10,000$27.38$273,800.00  
1/8/2024Christine Marie UtterCAOSell1,188$28.64$34,024.32  
1/8/2024Eric PauwelsInsiderSell1,569$28.64$44,936.16  
1/8/2024Mark Elliott BouldingVPSell1,457$28.64$41,728.48  
1/8/2024Matthew B KleinCEOSell2,237$28.64$64,067.68  
1/8/2024Michael SchmertzlerDirectorSell1,500$27.81$41,715.00  
1/5/2024Matthew B KleinCEOSell10,107$27.15$274,405.05  
12/12/2023Pierre GravierCFOBuy7,700$25.81$198,737.00  
(Data available from 1/1/2013 forward)

PTCT Insider Trading Activity - Frequently Asked Questions

5.50% of PTC Therapeutics stock is owned by insiders. Learn more on PTCT's insider holdings.

The following insider purchased PTCT shares in the last 24 months: Pierre Gravier ($198,737.00).

Insiders have purchased a total of 7,700 PTCT shares in the last 24 months for a total of $198,737.00 bought.

The following insiders have sold PTCT shares in the last 24 months: Alethia Young ($465,006.76), Allan Steven Jacobson ($1,540,640.00), Christine Marie Utter ($1,789,819.91), David P Southwell ($1,162,900.42), Emily Luisa Hill ($418,274.36), Emma Reeve ($238,256.40), Eric Pauwels ($136,960.42), Jerome B Zeldis ($764,800.00), Lee Scott Golden ($20,666.12), Mark Elliott Boulding ($3,341,241.50), Matthew B Klein ($615,145.76), Michael Schmertzler ($41,715.00), Neil Gregory Almstead ($63,658.94), Pierre Gravier ($77,191.38), and Stuart Walter Peltz ($246,486.20).

Insiders have sold a total of 243,118 PTC Therapeutics shares in the last 24 months for a total of $10,922,763.17 sold.

PTC Therapeutics Key Executives



This page (NASDAQ:PTCT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners